Drugs / MEDI7352
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04770428 | Apr → Dec 2021 | osteoarthritis, knee | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02508155 | Nov 2015 → Dec 2020 | chronic pain syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT04675034 | Dec 2020 → Aug 2023 | osteoarthritis, knee | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT03755934 | Nov 2018 → Jun 2023 | neuropathy, painful | AstraZeneca | Terminated | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI7352 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04675034 ↗ |
| Route | Intravenous | “dosed by IV infusion” NCT02508155 ↗ |